NYSE:CTLT - Catalent Stock Price, News, & Analysis

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) issued its quarterly earnings results on Tuesday, February, 5th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.08. The company earned $623 million during the quarter, compared to analysts' expectations of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The business's quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the business earned $0.45 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Catalent.

Catalent updated its FY 2019 earnings guidance on Tuesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.5-2.59 billion, compared to the consensus revenue estimate of $2.51 billion.

8 brokerages have issued 12 month price objectives for Catalent's stock. Their forecasts range from $45.00 to $55.00. On average, they expect Catalent's stock price to reach $48.4286 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for Catalent.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Media headlines about CTLT stock have trended somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Catalent earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.

Some companies that are related to Catalent include Centene (CNC), Eisai (ESALY), Fresenius Medical Care AG & Co. (FMS), TERUMO CORP/ADR (TRUMY), McKesson (MCK), LONZA GRP AG/ADR (LZAGY), Fresenius Medical Care AG & Co. KGaA (FME), COLOPLAST A/S/ADR (CLPBY), Canopy Growth (WEED), Align Technology (ALGN), Cerner (CERN), IDEXX Laboratories (IDXX), Incyte (INCY), Smith & Nephew (SNN) and AmerisourceBergen (ABC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Energy Transfer LP Unit (ET), Abbott Laboratories (ABT), Alibaba Group (BABA), Applied Materials (AMAT), Nucor (NUE), Cornerstone Total Return Fund (CRF), AbbVie (ABBV), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM) and Intuitive Surgical (ISRG).

Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.85%), FMR LLC (2.46%), Brown Advisory Inc. (1.98%), D. E. Shaw & Co. Inc. (1.63%), GW&K Investment Management LLC (1.27%) and Oregon Public Employees Retirement Fund (1.24%). Company insiders that own Catalent stock include Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, John J Greisch, John R Chiminski, Lance Miyamoto, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Macquarie Group Ltd., Westfield Capital Management Co. LP, Impax Asset Management Group plc, Bank of America Corp DE, Bank of New York Mellon Corp, SG Americas Securities LLC and Colony Group LLC. Company insiders that have sold Catalent company stock in the last year include Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Jennison Associates LLC, D. E. Shaw & Co. Inc., First Trust Advisors LP, Brown Advisory Inc., BlackRock Inc. and Forsta AP Fonden. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, John J Greisch and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $42.29.

Catalent has a market capitalization of $6.16 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

The official website for Catalent is http://www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]